Status:
COMPLETED
RFA for Treatment of Intermediate Stage HCC
Lead Sponsor:
Benha University
Collaborating Sponsors:
Beni-Suef University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
In Egypt, chronic hepatitis C virus (HCV) is the most prevalent cause of hepatoma. The study aims to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate ver...
Eligibility Criteria
Inclusion
- Patients were early and intermediate-stage HCC (BCLC stage A and B).
- Patients accepted to be treated by percutaneous radiofrequency ablation in the Interventional Ultrasonography Unit.
- Patients with early-stage-HCC should have up to 3 tumors, all smaller than 3 cm with a Child-Pugh A score.
- Patients with intermediate-stages-HCC should have multinodular HCC (\>3 nodules \<3 cm) or single focal lesion more than 3 cm, with Child-Pugh Score A or B liver cirrhosis, international normalized ratio (INR) less than 1.7, and platelet count more than 50,000/cm.
Exclusion
- Patients with HCC with and vascular spread (portal vein thrombosis), lymph node metastasis or distant metastasis, subcapsular lesions, or lesions with close vicinity to the gall bladder, bowel, or portal vein.
- Patients with clinically decompensated liver disease (Child-Pugh Score C liver cirrhosis).
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05281783
Start Date
October 1 2018
End Date
August 1 2021
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Interventional Ultrasonography Unit, Tropical Medicine Department, Beni-Suef University Hospitals
Banī Suwayf, Egypt